These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29986171)

  • 1. Correlates of neurocognitive functions in individuals at ultra-high risk for psychosis - A 6-month follow-up study.
    Sanada K; de Azúa SR; Nakajima S; Alberich S; Ugarte A; Zugasti J; Vega P; Martínez-Cengotitabengoa M; González-Pinto A
    Psychiatry Res; 2018 Oct; 268():1-7. PubMed ID: 29986171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurocognitive impairments in individuals at ultra-high risk for psychosis: Who will really convert?
    Bang M; Kim KR; Song YY; Baek S; Lee E; An SK
    Aust N Z J Psychiatry; 2015 May; 49(5):462-70. PubMed ID: 25425742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and serum brain-derived neurotrophic factor (BDNF) levels and their association with neurocognition in at-risk mental state, first episode psychosis and chronic schizophrenia patients.
    Heitz U; Papmeyer M; Studerus E; Egloff L; Ittig S; Andreou C; Vogel T; Borgwardt S; Graf M; Eckert A; Riecher-Rössler A
    World J Biol Psychiatry; 2019 Sep; 20(7):545-554. PubMed ID: 29938562
    [No Abstract]   [Full Text] [Related]  

  • 4. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial.
    Bolt LK; Amminger GP; Farhall J; McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Allott KA
    Schizophr Res; 2019 Apr; 206():67-74. PubMed ID: 30558978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurocognitive predictors of transition to psychosis: medium- to long-term findings from a sample at ultra-high risk for psychosis.
    Lin A; Yung AR; Nelson B; Brewer WJ; Riley R; Simmons M; Pantelis C; Wood SJ
    Psychol Med; 2013 Nov; 43(11):2349-60. PubMed ID: 23388122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma brain-derived neurotrophic factor levels, learning capacity and cognition in patients with first episode psychosis.
    Ruiz de Azua S; Matute C; Stertz L; Mosquera F; Palomino A; de la Rosa I; Barbeito S; Vega P; Kapczinski F; González-Pinto A
    BMC Psychiatry; 2013 Jan; 13():27. PubMed ID: 23320462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis.
    Lin A; Wood SJ; Nelson B; Brewer WJ; Spiliotacopoulos D; Bruxner A; Broussard C; Pantelis C; Yung AR
    Schizophr Res; 2011 Oct; 132(1):1-7. PubMed ID: 21763109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive functioning in individuals at ultra-high risk for psychosis, first-degree relatives of patients with psychosis and patients with first-episode schizophrenia.
    Hou CL; Xiang YT; Wang ZL; Everall I; Tang Y; Yang C; Xu MZ; Correll CU; Jia FJ
    Schizophr Res; 2016 Jul; 174(1-3):71-76. PubMed ID: 27197904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Social cognition and neurocognition as predictors of conversion to psychosis in individuals at ultra-high risk.
    Kim HS; Shin NY; Jang JH; Kim E; Shim G; Park HY; Hong KS; Kwon JS
    Schizophr Res; 2011 Aug; 130(1-3):170-5. PubMed ID: 21620681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations between facial affect recognition and neurocognition in subjects at ultra-high risk for psychosis: A case-control study.
    Randers L; Jepsen JRM; Fagerlund B; Nordholm D; Krakauer K; Hjorthøj C; Glenthøj B; Nordentoft M
    Psychiatry Res; 2020 Aug; 290():112969. PubMed ID: 32450415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive functioning in at-risk mental states for psychosis and 2-year clinical outcome.
    Simon AE; Grädel M; Cattapan-Ludewig K; Gruber K; Ballinari P; Roth B; Umbricht D
    Schizophr Res; 2012 Dec; 142(1-3):108-15. PubMed ID: 23025995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying neurocognitive markers for outcome prediction of global functioning in individuals with first-episode and ultra-high-risk for psychosis.
    Sawada K; Kanehara A; Sakakibara E; Eguchi S; Tada M; Satomura Y; Suga M; Koike S; Kasai K
    Psychiatry Clin Neurosci; 2017 May; 71(5):318-327. PubMed ID: 28294477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. History of childhood physical trauma is related to cognitive decline in individuals with ultra-high risk for psychosis.
    Üçok A; Kaya H; Uğurpala C; Çıkrıkçılı U; Ergül C; Yokuşoğlu Ç; Bülbül Ö; Direk N
    Schizophr Res; 2015 Dec; 169(1-3):199-203. PubMed ID: 26386899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study.
    Zhang Y; Fang X; Fan W; Tang W; Cai J; Song L; Zhang C
    Psychopharmacology (Berl); 2018 Apr; 235(4):1191-1198. PubMed ID: 29392373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General intellectual functioning as a buffer against theory-of-mind deficits in individuals at ultra-high risk for psychosis.
    Hur JW; Byun MS; Shin NY; Shin YS; Kim SN; Jang JH; Kwon JS
    Schizophr Res; 2013 Sep; 149(1-3):83-7. PubMed ID: 23810120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder.
    Dias VV; Brissos S; Frey BN; Andreazza AC; Cardoso C; Kapczinski F
    Bipolar Disord; 2009 Sep; 11(6):663-71. PubMed ID: 19689509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurocognition and social cognition in youth and young adults at ultra-high-risk for psychosis and bipolar disorder.
    Bora E; Eyuboglu MS; Cesim E; Demir M; Yalincetin B; Ermis C; Özbek Uzman S; Sut E; Demirlek C; Verim B; Baykara B; Akay A; İnal N; Akdede BB
    Schizophr Res; 2024 Apr; 266():58-65. PubMed ID: 38368706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis.
    Velthorst E; Nieman DH; Becker HE; van de Fliert R; Dingemans PM; Klaassen R; de Haan L; van Amelsvoort T; Linszen DH
    Schizophr Res; 2009 Apr; 109(1-3):60-5. PubMed ID: 19272756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurocognitive functioning before and after the first psychotic episode: does psychosis result in cognitive deterioration?
    Becker HE; Nieman DH; Wiltink S; Dingemans PM; van de Fliert JR; Velthorst E; de Haan L; van Amelsvoort TA; Linszen DH
    Psychol Med; 2010 Oct; 40(10):1599-606. PubMed ID: 20132582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Working memory as a predictor of negative symptoms and functional outcome in first episode psychosis.
    González-Ortega I; de Los Mozos V; Echeburúa E; Mezo M; Besga A; Ruiz de Azúa S; González-Pinto A; Gutierrez M; Zorrilla I; González-Pinto A
    Psychiatry Res; 2013 Mar; 206(1):8-16. PubMed ID: 22985548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.